中央明确明年优化药品集中采购 可以从哪些方面入手？

Core Viewpoint - The Central Economic Work Conference held in Beijing on December 10-11 outlined key tasks for economic work in the coming year, including optimizing drug centralized procurement and deepening medical insurance payment reform [1]. Group 1: Drug Centralized Procurement - Since the launch of the "4+7" centralized procurement pilot by the National Healthcare Security Administration (NHSA) in November 2018, eleven batches of drug procurement have been conducted, successfully procuring 490 types of drugs [1]. - The goals of drug centralized procurement include reducing the economic burden on insured individuals, improving the efficiency of medical insurance fund usage, and encouraging companies to transition towards innovation [1]. - The eleventh batch of centralized procurement, which produced results on October 27, 2025, included 55 types of drugs covering common medications in various fields such as anti-infection, anti-allergy, anti-tumor, and blood sugar regulation [1]. Group 2: Optimization of Procurement Rules - The eleventh batch of procurement achieved its expected goals of "stabilizing clinical use, ensuring quality, countering excessive competition, and preventing collusion" by aligning selected products with medical institution needs, raising qualification thresholds for bidding companies, and guiding rational pricing [1]. - There is ongoing attention on how to further counter excessive competition in future drug procurements, with suggestions for establishing a minimum bidding price to provide more certainty for companies [2]. - Experts suggest that procurement rules could be further strengthened around the four dimensions of "stabilizing clinical use, ensuring quality, countering excessive competition, and preventing collusion," including potentially setting a "bottom price" for bids [2].